Journal article
Dose–response study of recombinant human soluble thrombomodulin (ART‐123) in the prevention of venous thromboembolism after total hip replacement
Abstract
BACKGROUND: Recombinant human soluble thrombomodulin (ART-123) is composed of the active, extracellular, domain of thrombomodulin. ART-123 binds to thrombin and this complex converts protein C into the natural anticoagulant activated protein C. This study was performed to identify an effective and safe dose of ART-123 for prevention of venous thromboembolism after elective, unilateral total hip replacement.
METHODS AND RESULTS: An open-label, …
Authors
KEARON C; COMP P; DOUKETIS J; ROYDS R; YAMADA K; GENT M
Journal
Journal of Thrombosis and Haemostasis, Vol. 3, No. 5, pp. 962–968
Publisher
Elsevier
Publication Date
May 2005
DOI
10.1111/j.1538-7836.2005.01251.x
ISSN
1538-7933
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedArthroplasty, Replacement, HipBandagesDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayFemaleFibrinolytic AgentsHemoglobinsHemorrhageHumansMaleMiddle AgedPhlebographyPostoperative ComplicationsProtein CRecombinant ProteinsThromboembolismThrombomodulinTime FactorsTreatment OutcomeVenous Thrombosis